Currently Enrolling Trials
Palmetto Clinical Research is taking part in a clinical research study called the PROVENT Study. The purpose of this clinical research study is to learn more about a combination of two investigational monoclonal antibodies for the prevention of COVID-19, the disease caused by the coronavirus (SARS-CoV-2). Antibodies are protein molecules that the body produces to help fight infections.
If you take part, you will be in the PROVENT Study for approximately 1 year. You will have 8 visits at the study center and regular phone calls, emails, or text messages. Additional visits may be required if you develop symptoms of COVID-19 during the study.
You may be able to take part if you:
- are 18 years of age or older
- do not have a previously confirmed diagnosis of COVID-19
- have an increased risk of getting COVID-19 (due to location, employment,
or personal circumstances)
- are less likely than most adults to benefit from a vaccine (for example,
due to older age, obesity, or immunosuppression from a health condition
Not everyone will qualify to take part. The study doctor or study team will check other requirements before you can participate in the study.
Your participation in this study will help us learn more about the investigational monoclonal antibodies and COVID-19. The results may help prevent COVID-19 in the future.
This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a). To learn more, click here.
The RiNeuD study is a clinical research study for people who have type 1 or type 2 diabetes that has led to painful DPN. The goal of the RiNeuD study is to find out if the study medication can provide relief from the pain, tingling, and numbness associated with painful DPN. The study medication may be able to restore cells, called neurons, that transport messages between the brain and other parts of the body.
Who can join the study?
You may be able to join the RiNeuD study if you meet the following study requirements*:
- Between 18 and 80 years of age
- Diagnosed with diabetes (type 1 or type 2) at least 6 months ago
- Have pain, tingling, numbness, or weakness in the hands, legs or feet
Endometriosis is a painful disorder of the uterus affecting 6-10% of women of childbearing age. Endometriosis affects daily activities, social relationships, sexuality and sexual activity, and mental health. This study will evaluate how well elagolix in combination with combined oral contraceptives (COC) works within the body and/or how safe it is compared to placebo (does not contain treatment drug). This study will assess the dysmenorrhea (painful periods) response in participants with endometriosis and associated pain. To learn more about this study, call us at 843-851-7098 or click here.
This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab (Repatha) on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event. To learn more, click here.
Triglycerides are a type of fat that can be measured in the blood. They are the most common type of fat in the human body. They can come directly from foods, especially butter, oils, and other fatty foods, including red meat. Having persistently high levels of triglycerides (sometimes called severe hypertriglyceridemia) can raise the risk of heart disease and stroke.
This study is designed to assess the efficacy, safety, and tolerability of different doses and dose regimens (QW or every 2 weeks [Q2W]), subcutaneous (SC) dosing of BIO89-100 compared to placebo in subjects with Severe Hypertriglyceridemia (SHTG). To learn more about this study, click here.
Consider joining the TRAVERSE research study for men age 45-80 who have symptoms of low testosterone (hypogonadism) and have a history or risk of heart disease or stroke.
If you volunteer and qualify, your participation will last up to approximately 5 years. To learn more visit our contact us page or click here.
Randomized, double-blind, parallel-group, multicenter study to assess efficacy, safety, and tolerability of oral tropifexor & licogliflozin combination therapy, compared to each monotherapy, for treatment of adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis. To learn more, click here.
This is a multi-center, randomized, double-blind, parallel group, placebo controlled trial to evaluate the contribution of Triamcinolone Hexacetonide (TH) to pain relief, both in terms of magnitude and duration, when used within a single injection of Cingal® compared to a single injection of TH in subjects with OA of the knee.To learn more, click here.
Don't see a study that you qualify for?
Contact us to be added to interest list and you’ll be the first to know about our future studies! Send us a message by clicking the “contact us” button or call us at +1-843-851-7098.